29.37  0.51 (1.77%)		10-02 16:00
Open: 28.94 High: 29.42 Volume: 270,231		Pre. Close: 28.86 Low: 28.88 Market Cap: 1,935(M)

Short term
Mid term
Targets	6-month :	35.27	1-year :	37.85
Resists	First :	30.2	Second :	32.4
Pivot price	29.13
Supports	First :	26.62	Second :	22.15
MAs	MA(5) :	29.44	MA(20) :	28.71
	MA(100) :	28.49	MA(250) :	30.51
MACD	MACD :	0.3	Signal :	0.3
%K %D	K(14,3) :	46	D(3) :	48.5
RSI	RSI(14): 53.1
52-week	High :	37	Low :	25.68

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ LKFT ] has closed below upper band by 44.6%. Bollinger Bands are 44.4% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 8 days. This is a sign that the current trend might continue.

If tomorrow:	Open lower	Open higher
High:	29.45 - 29.59	29.59 - 29.71
Low:	28.54 - 28.7	28.7 - 28.85
Close:	29.12 - 29.38	29.38 - 29.6

Lakefront Biotherapeutics NV, formerly Galapagos NV, is a biotechnology company that focuses on transforming patient outcomes through scientific innovation. It is dedicated to building a pipeline of medicines for patients with serious diseases in therapeutic areas of unmet need, prioritizing oncology and immunology & inflammation programs. The company's clinical-stage portfolio is anchored by potential first-in-class treatments for autoimmune diseases.

Wed, 30 Sep 2026
Lakefront Biotherapeutics NV (NASDAQ: LKFT) Stock Price, News & Analysis - kalkine.ca

Wed, 30 Sep 2026
Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) Stock Now Rated "Moderate Buy" by Sell-Side Analysts - MarketBeat

Tue, 29 Sep 2026
106,060 shares bought back Sept. 21–25 by Lakefront Biotherapeutics (LKFT). - stocktitan.net

Tue, 29 Sep 2026
Acquisition of Own Shares - GlobeNewswire

Wed, 23 Sep 2026
Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) Upgraded to "Outperform" at Royal Bank Of Canada - MarketBeat

Wed, 23 Sep 2026
Lakefront (LKFT) spends millions on buybacks, but how many shares came back? - stocktitan.net

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Outperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Neutral
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Underperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Outperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Outperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	65 (M)
Shares Float	474 (M)
Held by Insiders	25.4 (%)
Held by Institutions	23.6 (%)
Shares Short	2,970 (K)
Shares Short P.Month	2,320 (K)

EPS	10.44
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	2.89
Profit Margin	60.2 %
Operating Margin	-359.3 %
Return on Assets (ttm)	9.9 %
Return on Equity (ttm)	20.1 %
Qtrly Rev. Growth	-81.5 %
Gross Profit (p.s.)	10.22
Sales Per Share	15.12
EBITDA (p.s.)	8.68
Qtrly Earnings Growth	0 %
Operating Cash Flow	-227 (M)
Levered Free Cash Flow	138 (M)

PE Ratio	2.81
PEG Ratio	0
Price to Book value	10.16
Price to Sales	1.94
Price to Cash Flow	-8.48

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.